Inflammation Reprograms Fibro-Adipogenic Progenitors (FAPs) to Form Immunopathogenic Niches in Myositis
Background
Despite immunosuppressive treatments, Idiopathic inflammatory myopathies (IIMs) are characterized by persistent muscle inflammation and fibrosis, with mechanisms of disease perpetuation remaining unclear. Current therapies often fall short, highlighting a critical gap in understanding the cellular drivers of chronic disease activity. Tissue-resident stromal cells, specifically fibro-adipogenic progenitors (FAPs), are known for their role in muscle repair but their contribution to chronic inflammation in IIMs has been largely unrecognized. This study investigates how FAPs adapt to inflammatory microenvironments and sustain immunopathogenic niches, potentially offering novel therapeutic targets beyond traditional immunosuppression.
Study Design
Researchers investigated the role of FAPs in myositis using single-nucleus and spatial transcriptomics on muscle biopsies from 24 IIM patients and 6 non-diseased controls. They characterized FAP adaptation to different immune environments (T-cell vs. macrophage-centric). To elucidate mechanistic drivers, primary human FAPs were exposed to TGF-β and EGF to observe changes in differentiation and gene accessibility. Ligand-receptor analyses and trajectory modeling were employed to identify key signaling pathways and transcription factors involved in FAP reprogramming.
Results
FAPs demonstrated remarkable plasticity, adapting their gene expression programs to their local tissue context, favoring T-cell-centric programs in T-cell-rich environments and myeloid programs in macrophage-rich areas. Spatially, FAPs formed inflammatory niches by co-localizing with muscle stem cells and activated macrophages, facilitating crucial cell-to-cell communication. > A dual-input mechanism was identified where infiltrating immune cells (via TGF-β) and myofibers (via EGF) converge on the AP-1 transcription factor, driving FAP differentiation towards a pro-inflammatory and pro-fibrotic phenotype. Mechanistically, exposure of primary human FAPs to TGF-β and EGF induced a primed state by altering the accessibility to AP-1 regulatory elements, suggesting a direct role in transcriptional reprogramming. These findings reveal a previously unrecognized role of FAPs in sustaining IIM pathology.
Key Findings
- FAPs adapt their gene expression to local immune environments (T-cell vs. macrophage-centric) in IIM patients.
- FAPs form inflammatory niches by co-localizing with muscle stem cells and activated macrophages.
- A dual-input mechanism via
TGF-β(immune cells) andEGF(myofibers) drives FAP reprogramming. - The
AP-1transcription factor is a key convergence point forTGF-βandEGFsignaling in FAPs. - Exposure to
TGF-βandEGFaltersAP-1regulatory element accessibility in human FAPs.
Why It Matters
This research fundamentally shifts our understanding of Idiopathic inflammatory myopathies (IIMs) by identifying fibro-adipogenic progenitors (FAPs) as active participants in chronic inflammation and fibrosis, rather than passive bystanders. Targeting FAP reprogramming could offer a novel therapeutic strategy to break the cycle of persistent muscle damage and inflammation, potentially overcoming resistance to current immunosuppressive treatments. This opens avenues for developing therapies that specifically modulate FAP behavior, moving beyond broad immune suppression. While not immediately a usable protocol, it highlights specific pathways (TGF-β, EGF, AP-1) for future drug development, suggesting that combination therapies targeting both immune cells and stromal FAPs might be more effective.
myositis
iim
inflammation
fibrosis
fibro-adipogenic-progenitors
faps